Soluble βamyloid1‐42: a critical player in producing behavioural and biochemical changes evoking depressive‐related state?
- 29 March 2010
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 159 (8), 1704-1715
- https://doi.org/10.1111/j.1476-5381.2010.00669.x
Abstract
Depression is common in early phases of Alzheimer's disease (AD) and may represent prodromal symptoms of dementia. Recent reports suggest that early memory deficits and neuropsychiatric symptoms are caused by soluble rather than aggregated betaamyloid (Abeta). Thus, we investigated the effects of soluble Abeta(1-42) on working memory and depressive/anxiety-related behaviour in rats and on 5-hydroxytryptaminergic neurotransmission and neurotrophin content in various brain regions. Behavioural reactivity to novel object recognition, open field, elevated plus maze and forced swimming test were assessed 7 days after i.c.v. injection of Abeta(1-42) or its vehicle. BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) mRNA and protein levels and 5-hydroxytriptamine (5-HT) content were measured in the prefrontal cortex (PFC), striatum (STR) and nucleus accumbens (NAc). Abeta(1-42) did not affect the ability to distinguish between familiar and novel objects, but Abeta-treated rats exhibited an increase in forced swimming immobility. No differences were revealed between experimental groups in the elevated plus maze test or in self-grooming (evaluated in the open field). In the PFC, but not STR or NAc, Abeta-injected rats exhibited a selective reduction in 5-HT content, BDNF and NGF expression. Our data suggest that soluble Abeta-treated rats have a depressive, but not anxiogenic-like, profile, accompanied by brain region-dependent alterations in the expression of neurotrophins and 5-hydroxytryptaminergic neurotransmission. Hence, these alterations induced by soluble Abeta might be sensitive indicators of early phases of AD and possible risk factors for the expression of neuropsychiatric symptoms in AD.Keywords
This publication has 72 references indexed in Scilit:
- The molecular neurobiology of depressionNature, 2008
- Amyloid-Associated DepressionArchives of General Psychiatry, 2008
- Differential regulation of neurotrophins and serotonergic function in mice with genetically reduced glucocorticoid receptor expressionExperimental Neurology, 2007
- The use of the elevated plus maze as an assay of anxiety-related behavior in rodentsNature Protocols, 2007
- Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmissionPharmacology & Therapeutics, 2006
- Depression and Risk for Alzheimer DiseaseArchives of General Psychiatry, 2006
- Synaptic plasticity disruption by amyloid β protein: modulation by potential Alzheimer's disease modifying therapiesBiochemical Society Transactions, 2005
- Natural oligomers of the amyloid-β protein specifically disrupt cognitive functionNature Neuroscience, 2004
- Pathways towards and away from Alzheimer's diseaseNature, 2004
- Elevated levels of Aβ1–40 and Aβ1–42 do not alter the binding sites of nicotinic receptor subtypes in the brain of APPswe and PS1 double transgenic miceNeuroscience Letters, 2002